Previous 10 | Next 10 |
Viatris ( NASDAQ: VTRS ) is scheduled to announce Q4 earnings results on Monday, February 27th, before market open. The consensus EPS Estimate is $0.72 (vs. -$0.22 last year) and the consensus Revenue Estimate is $3.99B (-7.9% Y/Y). Over the last 1 year, VTRS has beaten EPS ...
Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...
To afford a dividend, companies must make consistent profits, preferably via a business model that won't need to change significantly over time. That means they're often priced at a premium because investors love consistency, as they well should. But sometimes, a window of opportunity opens t...
Summary Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article. In 2023, the company's investors should receive a dividend of $2.28 per share, up...
Viatris ( NASDAQ: VTRS ) continued to trade lower pre-market Friday as BMO Capital Markets downgraded the drugmaker to Market Perform from Outperform, citing a lack of clarity on the company’s next phase of growth profile. “VTRS progressing well with strategic initiative...
Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...
Summary Anda's revenue generated $450 million for the company in the last three months of 2022, up $95 million from Q4 2022, driven by substantially increased demand for the company's services. Teva's European segment profit was $1,496 million in 2022, slightly up year-over-year, even t...
Viatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 PR Newswire PITTSBURGH , Feb. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its fourth quarter and full year 2022 financial results on Mon...
The Nasdaq Composite is often associated with high-powered growth stocks. But there are also many quality dividend stocks in there as well, which are also focused on growth. Three stocks that could potentially give you the best of both worlds are Viatris (NASDAQ: VTRS) , Comcast ...
Summary Davis Selected Advisers 13F portfolio value increased from $14.06B to $14.71B this quarter. They increased Meta Platforms, Amazon.com, and Markel while reducing Cigna, JD.com, and Coupang. The top three positions are Berkshire Hathaway, Wells Fargo, and Capital One Financial...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...